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INTRODUCTION
Despite the advances that have been made in surgery, chemother-
apy and radiation therapy, there has been limited improvement
in the survival of patients with head and neck cancer. The mole-
cular studies that have focused on the pathogenesis of head and
neck squamous cell carcinoma (HNSCC) have developed new
approaches to identify the higher risk patients who have progres-
sion or recurrence of disease and to help patients with multimodal-
ities and targeted therapy. The serum levels of cytokines and an-
giogenesis factors may be applicable as tumor markers for the ea-
rly detection of HNSCC, and as biomarkers to predict the out-
come of patients with HNSCC (1-3).
In our previous report (4), we reported that the detection of a
telomerase expression in the peripheral blood mononuclear cells
(PBMCs) of HNSCC patients was a simple method and telomer-
ase is a very useful molecular marker for assessing the progres-
sion and prognosis of HNSCC. In addition, they suggested two
possible mechanisms for the telomerase expression in the PBMCs
of the HNSCC patients. First, a number of soluble factors are se-
creted either by the tumor cells themselves or by the surround-
Objectives. This study investigated the telomerase expression in peripheral blood mononuclear cells (PBMCs) and the
relationship between the serum level of several soluble factors such as vascular endothelial growth factor (VEGF),
hepatocyte growth factor, interleukin (IL)-6, IL-8, and matrix metallopeptidase-9 and the clinicopathological fea-
tures of patients with head and neck squamous cell carcinoma (HNSCC).
Methods. Peripheral blood samples were collected from 50 HNSCC patients and 15 normal controls. The telomerase activ-
ity in the PBMCs was measured by Telomere Repeat Amplification Protocols. The serum levels of the soluble fac-
tors were analyzed by enzyme-linked immunosorbent assay.
Results. The expression of telomerase in the PBMCs of HNSCC patients was significantly correlated with the N and Am-
erican Joint Committee on Cancer (AJCC) stages. The serum VEGF level was significantly higher in the patients
with an advanced T stage, N stage and AJCC stage. Serum VEGF was significantly related with the expression of
telomerase in the PBMCs. The telomerase expression and the VEGF expression were shown to be independent
factors associated with poor survival.
Conclusion. The telomerase expression in the PBMCs and the serum VEGF level of HNSCC patients were significantly
correlated with the N stage, the AJCC stage and the prognosis.
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ed by these soluble factors and these cells have the high rate of
expressing telomerase. Second, PBMCs can be activated by the
antigenic stimulation of tumor cells in metastatic lymph nodes.
From the studies concerned with the growth, inflammatory and
angiogenesis factors related to HNSCC, we selected several po-
tential pathologic and prognostic markers such as vascular endo-
thelial growth factor (VEGF), hepatocyte growth factor (HGF),
interleukin (IL)-6 and IL-8, and matrix metalloproteinase (MMP)-
9. VEGF, IL-6, and IL-8 were found to be secreted by many estab-
lished and freshly cultured HNSCC cell lines and these factors
were detectable by immunohistochemistry in tumor specimens
(1-3, 5, 6). HGF and MMP-9 were detectable at increased con-
centrations in the serum of many patients with NHSCC in other
studies (6, 7).
We designed this study to examine the telomerase expression
of PBMCs and the serum level of these soluble factors in patient
with NHSCC and in normal controls. Our aims were to investi-
gate: 1) the level of the telomerase expression and serum level
of several soluble factors in patient with HNSCC and as com-
pared to normal controls, 2) the relationship between the clini-
cal characteristics of patient with HNSCC and the levels of bio-
markers, 3) whether the telomerase expressions in PBMCs are
correlated with one other, and 4) whether these biomarkers are
associated with survival. 
MATERIALS AND METHODS
Patients
The subjects were 50 patients with HNSCC that was confirmed
at Pusan National University Hospital during the period from
January to December 2004. All the subjects signed an IRB ap-
proved informed consent form prior to participation in this study.
The patients who showed a poor general condition, those who
were previously treated for cancer, and those who had autoim-
mune disease were excluded. Of the 50 patients, 41 (82%) were
men and 9 (18%) were women. Their median age was 61.5 yr
(range, 41 to 80 yr). The primary sites was the larynx in 25 cases,
the hypopharynx in 9 cases, the oropharynx in 7 cases, the oral
cavity in 7 cases and the maxillary sinus in 2 cases.
All the treatment was performed with surgery and/or radio-
therapy and with or without chemotherapy, as recommended by
a multidisciplinary tumor board. Fourteen patients underwent
resection surgery and corresponding neck dissection, and 9 rec-
eived adjuvant radiotherapy. Twelve patients were received ra-
diotherapy only. Twenty-four patients underwent concurrent
chemoradiotherapy with weekly cisplatin and radiotherapy. We
used the American Joint Committee on Cancer (AJCC) version
6 TNM criteria for delineating the stage. The normal controls were
10 healthy men and 5 healthy women aged 25 to 65 with no his-
tory of chronic systemic disease or malignancies. After comple-
tion of treatment, the patients underwent routine surveillance
every 1 to 3 months. The median follow-up period for the sur-
viving patients was 25 months (range, 10 to 45 months).
Separation of the PBMCs and serum from the peripheral
blood
Blood samples (12 mL) were collected in heparinized tubes at the
time of the initial evaluation from the normal controls and the
HNSCC patients before surgery, chemotherapy and/or radiother-
apy. The serum samples were obtained by centrifugation at 2,000
rpm for 20 min and they were stored at -80℃. The PBMCs were
separated by a Ficoll Hypaque density gradient and they were
stored at -80℃ until use.
Measurement of the serum level of soluble factors
The serum levels of soluble factors (VEGF, IL-6, IL-8, MMP-9, and
HGF) were analyzed by enzyme-linked immunosorbent assay
(ELISA) using Quantikine Immunoassay Kits. ELISAs were per-
formed according to the methods recommended by the manu-
facturer. After the development of the colorimetric reaction, the
optical density (OD) at 450 nm was quantified by an eight-chan-
nel spectrophotometer (Biotek Systems, Winoski, VT, USA), and
the OD readings were converted to picograms per milliliter (pg/
mL) on the basis of the standard curves obtained with recombi-
nant cytokine in each assay. Each sample was tested in duplicate.
The cytokine concentrations between the replicates varied by
less than 10% and they are represented as mean values.
Telomeric Repeat Amplification Protocol (TRAP) assay
in the PBMCs
The measurement and analysis of the telomerase activity of the
PBMCs were conducted through the use of the TRAPEZE
TM Telo-
merase Detection Kit (Oncor Co., Gaithersburg, MD, USA), wh-
ich is a modified the TRAP assay by Kim et al. (8).
The PBMCs were resuspended in 100 mL of lysis buffer (CH-
APS) and then they were incubated for 30 min at 4℃. To prepare
the extracted tissue, the stored tissues were thawed and then they
were immediately put into ice to keep them at 4℃. The lysates
were centrifuged at 12,000×g for 20 min at 4℃. The supernatants
were transferred into fresh Eppendorf tubes, and the protein con-
centration was measured. The concentrated protein was then dilut-
ed with 1× CHAPS lysis buffer to make a 1 mg/mL solution.
The TS primer (5′ -AATCCGTCGAGCAGAGTT-3′ ) to be used
for the TRAP reaction was labeled with g-32P-ATP (3,000 Ci/
mmol, 10 mCi/mL) and T4 polynucleotide kinase. The total am-
ount of the TRAP reaction solution was 25 mL: 2.5 mL of the 10×
TRAP buffer (200 mM Tris-HCl, pH 8.3, 15 mM MgCl2, 630 mM
KCl, 0.5% Tween 20, 10 mM EGTA, 0.1% BSA), 0.5 mL of the
50× dNTPs mix (25 mM each of dATP, dTTP, dGTP, and dCTP),
1 mL of the 32P-TS primer, 0.5 mL of the TRAP primer mix (RP
primer, K1 primer, TSK1 template), 0.2 mL of Taq polymerase
(5 units/mL; Takara Co., Otsu, Japan), 18.3 mL of distilled water
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and 2 mL of the specimen. The solution was put to reaction at
30℃ for 30 min in a thermal cycler (Mastercycler 5330, Eppen-
dorf Co., Hamburg, Germany) so that the telomerase that is sup-
posed to be included in the specimen could react. Next, the reac-
tion was terminated by heating for 30 sec at 94℃. Amplification
of the reaction product was repeated 30 times; one unit of
amplification consisted of 30 sec at 94℃ and 30 sec at 60℃.
Loading dye (0.25% bromophenol blue, 0.25% xylene cyanol,
50% glycerol, 50 mM EDTA, pH 8.0) was put into each reaction
tube, and electrophoresis was conducted on 12.5% polyacryla-
mide gel and 0.25× TBE buffer. The results were analyzed by
using a phosphorimager (Molecular Dynamics Co., Sunnyvale,
CA, USA). The samples that showed only bands of 36 bp were
determined to be negative. The samples with accompanying TRAP
products that had become longer by units of 6 bp (for examples,
50 bp and 56 bp, 62 bp and 68 bp, in addition to 36 bp) were
determined to be positive. The human kidney 239 cell lines were
used for the positive control, and distilled water was used for the
negative control.
Statistical analysis
Pearson’s chi-square test or the Wilcoxon signed rank test was
used to evaluate the associations between the telomerase activi-
Tumor markers Normal (n=15) Cancer (n=50) P-value
Table 1. The expression of tumor markers in the normal controls and
HNSCC group
Data are mean±SD (pg/mL).
HNSCC: head and neck squamous cell carcinoma; VEGF: vascular endo-
thelial growth factor; HGF: hepatocyte growth factor; IL: interleukin;  MMP:
matrix metalloproteinase.
All the values of VEGF, IL-6, IL-8, HGF and MMP-9 are expressed as means±SD (pg/mL).
*P=0.001; 
� P=0.009; 
� P=0.001; 
�P<0.001; 
‖P<0.001.
VEGF: vascular endothelial growth factor; IL: interleukin; HGF: hepatocyte growth factor; MMP: matrix metalloproteinase; HNSCC: head and neck squamous
cell carcinoma; N: negative; P: positive; WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; AJCC: American Joint Committee
on Cancer.
Telomerase (+) 26.7% (4/15) 84.0% (42/50) <0.001
VEGF 19.42±0.64 199.48±82.59 <0.001
HGF 0.89±3.47 125.04±327.80 0.056
IL-6 0.21±0.58 15.15±70.47 0.153
IL-8 154.46±195.02 88.79±223.36 0.451
MMP-9 3.78±2.86 12.61±8.88 <0.001
Parameters No.
Telomerase activity
N (%) P (%)
VEGF IL-6 IL-8 HGF MMP-9
Table 2. The association of telomerase, VEGF, IL-6, IL-8, HGF and MMP-9 with the clinicopathologic parameters of the HNSCC patients
Gender
Male 41 6 (14.6) 35 (85.4) 204.45±85.30 17.91±77.71 104.17±244.41 125.46±356.09 12.68±7.77
Female 9 2 (22.2) 7 (77.8) 177.16±69.08 2.59±2.70 18.76±13.03 123.13±155.43 12.32±13.47
Age
<60 18 4 (22.2) 14 (77.8) 222.82±94.71 4.51±11.62 19.93±20.10 66.78±112.08 13.25±7.27
≥60 32 4 (12.5) 28 (87.5) 186.35±73.27 21.14±87.59 127.53±272.64 157.81±399.85 12.25±9.77
Histologic grade
WD-MD 40 5 (12.5) 35 (87.5) 203.29±82.42 17.25±78.49 107.51±246.69 138.72±364.51 18.62±7.49
PD 10 3 (30.0) 7 (70.0) 184.19±85.89 6.75±15.43 13.92±10.34 70.28±71.44 17.83±12.20
T stages
T1-T2 37 7 (18.9) 30 (81.1) 176.61±68.84
� 6.93±23.64 87.49±223.44 160.13±375.50 13.64±9.60
T3-T4 13 1 (7.7) 12 (92.3) 264.54±86.26
� 38.55±133.42 92.52±232.21 25.17±34.06 9.69±5.79
N stages
N (-) 26 8 (30.8) 18 (69.2)* 160.05±73.44
� 3.82±9.92 112.97±262.27 145.82±425.54 13.54±10.58
N (+) 24 0 (0.0) 24 (100)* 242.18±70.78
� 27.43±100.85 62.60±173.62 102.52±176.29 11.6±6.67
AJCC stage
I-II 20 7 (35.0) 13 (65.0)
� 129.95±39.26
‖ 4.28±11.22 93.48±243.35 180.05±481.97 14.77±11.33
III-IV 30 1 (3.3) 26 (96.7)
� 245.83±70.42
‖ 22.41±90.40 85.67±213.24 88.36±160.90 11.18±6.62
Site
Larynx 25 2 (8.0) 23 (92.0) 179.93±69.59 6.83±27.42 134.54±295.57 151.23±436.17 12.38±7.44
Hyopharyx 9 2 (22.2) 7 (77.8) 238.14±116.01 3.74±2.48 27.66±26.19 139.23±232.43 13.21±12.10
Oropharyx 7 1 (14.3) 6 (85.7) 242.25±81.46 69.28±182.22 27.13±27.11 51.74±74.56 14.32±7.84
Oral cavity 7 2 (28.6) 5 (71.4) 166.19±63.52 9.04±18.25 85.61±189.56 119.21±158.47 9.63±10.45
Maxilla 2 1 (50.0) 1 (50.0) 236.52±1.29 2.47±3.49 18.99±2.98 10.65±11.27 17.30±3.13ty of the PBMCs or the serum levels of VEGF, HGF, IL-6, IL-8,
and MMP-9 and the clinicopathologic parameters, including age,
gender, the tumor site, the extent of tumor (the T and N stages
and the overall stage) and the histopathologic grade (well, mod-
erately, and poorly differentiated). This analysis was also used
to investigate the correlation between the telomerase activity of
PBMCs and the serum levels of VEGF, HGF, IL-6, IL-8, and MMP-
9 in the HNSCC patients.
We performed univariate analysis using the Kaplan-Meier me-
thod and log-rank testing to examine the predictive value of the
telomerase activity of the PBMCs and the serum levels of these
soluble factors for the 3 yr overall survival. The Cox proportion-
al hazards model was used for multivariate analysis. All the P-
values presented were 2-sided, and the significance level was set
at less than 0.05. 
RESULTS
Telomerase activity and the serum levels of VEGF and
MMP-9
Regarding the expression of telomerase in the PBMCs of the
HNSCC patients, 42 out of 50 (84%) were positive, and 8 cases
(16%) were negative. Of the 15 normal volunteers, 4 (26.7%)
were positive. The difference between the normal controls and
the HNSCC group for the telomerase expression of the PBMCs
was significant (P<0.001) (Table 1). The serum levels of VEGF
and MMP-9 of the HNSCC group were significantly higher than
those of the normal control group (P<0.001), but there were no
significant differences in the IL-6, IL-8 and HGF levels between
the two groups (Table 1). 
Telomerase activity and clinicopathologic parameters
The expression of telomerase in the PBMCs of the patients was
significantly correlated with the N classification (P=0.001) and
the AJCC stage (P=0.009). The patients with lymph node metas-
tasis and an advanced AJCC stage (stage III or IV) showed a high-
er positive telomerase expression (Table 2).
Serum levels of VEGF and clinicopathologic parameters 
There was no significant relationship between the serum levels
of HGF, IL-6, IL-8, and MMP-9 and the clinicopathologic para-
meters. However, the serum levels of VEGF were significantly
higher in the patients with an advanced T stage (T3 or T4) (P=
0.001), lymph node metastasis (P<0.001) and an advanced AJCC
stage (stage III or IV; P<0.001) (Table 2).
Correlation between the telomerase activity and serum
levels of VEGF
There were no significant relationship between the mean serum
levels of HGF, IL-6, IL-8, and MMP-9 and the expression of the
telomerase activity of the PBMCs in the HNSCC patients. How-
ever, the mean serum VEGF level was significantly related with
the expression of telomerase activity in the PBMCs (P=0.002)
(Table 3).
Survival analysis
As shown in Table 4, univariate analysis reveals that the 3-yr
survival rates were significantly associated with the N classifica-
tion (P=0.023), the AJCC stages (P=0.040), the telomerase ex-
pression (P=0.016) and the VEGF expression (P=0.028). The
Kaplan-Meier overall survival curves related to these prognos-
tic factors are shown in Fig. 1. On the multivariate analysis, the
N classification (P=0.025), the AJCC stages (P=0.042), the tel-
omerase expression (P=0.047) and the VEGF expression (P=
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Biomarker
Telomerse (-) Telomerse (+)
P-value
(n=8) (n=42)
Table 3. The relationship between the telomerase expression and
the levels of the serum biologic markers in the peripheral blood of
HNSCC patients
Data are mean±SD (pg/mL).
HNSCC: head and neck squamous cell carcinoma; VEGF: vascular endo-
thelial growth factor; HGF: hepatocyte growth factor; IL: interleukin; MMP:
matrix metalloproteinase.
VEGF 120.77±54.87 214.47±78.74 0.002
HGF 54.32±36.75 138.51±356.41 0.214
IL-6 2.61±2.38 17.54±76.80 0.282
IL-8 78.60±176.40 90.74±232.99 0.869
MMP-9 13.42±12.86 12.50±8.12 0.783
3 yr  Univariate  Multivariate
Characteristics survival analysis analysis
rate (%) (P-value) (P-value)
Table 4. The prognostic factors of HNSCC patients
Low VEGF, HGF, IL-6, IL-8, and MMP-9 are the patients with lower levels
than each of the mean levels, and high means higher levels than each of
the mean levels.
HNSCC: head and neck squamous cell carcinoma; WD: well differentiat-
ed; MD: moderately differentiated; PD: poorly differentiated; VEGF: vascu-
lar endothelial growth factor; HGF: hepatocyte growth factor; IL: interleukin;
MMP: matrix metalloproteinase.
Age (-60/>60) 83.3/75.0 0.271 0.275
Gender (male/female) 80.5/66.7 0.191 0.194
T classification (T1-2/T3-4) 86.5/53.8 0.072 0.074
N classification (N0/N+) 92.3/62.5 0.023 0.025
AJCC stage (I-II/III-IV) 95.0/66.7 0.040 0.042
Histologic grade (WD-MD/PD) 77.5/80.0 0.984 0.990
Telomerase (-/+) 100/73.8 0.045 0.047
VEGF (low/high) 92.3/62.5 0.028 0.029
HGF (low/high) 84.0/72.0 0.172 0.174
IL-6 (low/high) 76.9/79.2 0.870 0.874
IL-8 (low/high) 74.1/82.6 0.675 0.678
MMP-9 (low/high) 81.5/73.9 0.542 0.538190 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 4: 186-192, December 2009
0.029) were shown to be independent factors associated with
poor survival (Table 4).
DISCUSSION
The expression of telomerase activity in HNSCC tissue is a useful
indicator to determine the progression of disease and the prog-
nosis of these patients. Although telomerase activity has been
detected in normal human PBMCs, increased telomerase activity
has been observed in the PBMCs of HNSCC patients (4, 9). In
this study, the rate of the telomerase expression in the PBMCs
of the HNSCC patients was significantly higher than that of the
healthy volunteer control group (P<0.001). The telomerase ex-
pression in the PBMCs of the patients was significantly correlat-
ed with the N classification and the AJCC stage (P<0.05). These
findings are consistent with the results of Lee et al. (4). There have
been many reports on the activity of telomerase in the various
types of cancer patients (10-14). Compared with the existing me-
thod for extracting tissues specimen, this method that evaluates
the telomerase activity in PBMCs is less invasive, safer and more
convenient because it needs only blood samples of patients.
There have been some studies that cytokines and angiogenesis
factors may be potential useful as serum markers for the progno-
sis, progression, recurrence and survival of patient with HNSCC
(1-3, 5). We examined the serum levels of VEGF, MMP-9, HGF,
IL-6, and IL-8, which are well-known for their roles in the devel-
opment, progression and invasive growth of tumors (5). Although
the VEGF (P<0.001) and MMP-9 (P<0.001) levels were signif-
icantly higher than those of the normal control group, no signif-
icant differences of the others factors were observed between the
HNSCC group and the normal control group. However, Druzgal
et al. (1) reported that the serum levels of IL-6, IL-8, HGF, VEGF
and growth regulated oncogene were increased in the patients
with HNSCC as compared with those of the normal control group.
Gokhale et al. (6) reported that the serum level of IL-8 of the
HNSCC group was significantly different from that of the normal
control group, but the serum level of VEGF showed no significant
difference between the normal control group and the HNSCC
group. Hathaway et al. (2) reported that the serum levels of IL-1b,
tumor necrosis factor-a and IL-6 were higher in HNSCC patients
than those of chronic smokers. Ruokolainen et al. (7) reported that
the MMP-9 serum levels were significantly higher in the HNSCC
patients than those in the healthy controls. We suggest that the
Fig. 1. Kaplan-Meier overall survival curves. There are significant differences in the Kaplan-Meier overall survival curves related to the telomerase
expression and the serum vascular endothelial growth factor (VEGF) level. (A) Telomerase expression (P=0.045). (B) Serum VEGF level (P=
0.028). (C) Serum hepatocyte growth factor level (P=0.172). (D) Serum interleukin (IL)-6 level (P=0.870). (E) Serum IL-8 level (P=0.675). (F)
Serum matrix metalloproteinase-9 level (P=0.542).
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serum VEGF and MMP-9 levels may be helpful for making an
early diagnosis and for detecting recurrence. Further study is ne-
eded for the patients who have finished treatment and/or are
suspected to have recurrence.
Although the serum level of MMP-9 was significantly higher
than that of the normal control group, there was no correlation
between the serum level of other cytokines (IL-6, IL-8, and HGF)
and the clinicopathologic features of the HNSCC group. The ex-
pression of VEGF was higher for the late T stage patients than
that for the early T stage patients and it was increased in the pa-
tients with lymph node metastasis and an advanced AJCC stage.
This means that the expression of serum VEGF is increased in
patient with an advanced HNSCC stage. On the univariate and
multivariate analyses (P=0.028, P=0.029), the VEGF level was
an independent factor associated with poor survival. Kumar et
al. (15) presented that the significant increase of the serum VEGF
level is related to the clinical stage and lymph node metastasis in
patients with colorectal cancer. Teknos et al. (16) reported that
patients with advanced laryngeal carcinoma showed significant-
ly higher serum VEGF levels than did the healthy controls, and
elevated serum VEGF levels tended to indicate a more aggressive
disease state and poorer overall survival. Ruokolainen et al. (7)
reported that no correlation was found between the MMP-9 se-
rum levels and the histopathologic factors. Hathaway et al. (2)
reported that the serum levels of IL-8 significantly differed by the
T stage of HNSCC patients, IL-4 differed by the N stage and IL-
6 showed no significant difference by the T and N stages. Druzgal
et al. (1) reported that the serum levels of IL-6, IL-8, HGF, and
VEGF were increased in patients with HNSCC as compared to
the normal control group, but there was no significant relation-
ship between the serum levels of these factors and the disease-
free survival or overall survival. Further studies should be con-
sidered to obtain more significant results.
This study showed a significant relationship between the exp-
ression of telomerase in PBMCs and the serum VEGF that may
be secreted by the tumor cells. This result supports the first sug-
gestion of Lee et al. (4) that the telomerase expression in PBMCs
could be activated by several soluble factors, including VEGF.
Chiu and Harley (17) maintained that normal blood cells and
other somatic cells, including mature and stable lymphocytes,
rarely show a telomerase expression, but the activated mononu-
clear cells in the peripheral blood such as T and B lymphocytes
can show a telomerase expression by antigenic stimulation. In an
experimental animal model of hind limb ischemia, Zaccagnini et
al. (18) reported that VEGF causes the activation of telomerase
through the nitric oxide pathway in the process of new vessel
formation. Especially, Shao and Guo (19) mentioned that human
telomerase reverse transcriptase, which is a telomerase catalytic
subunit, behaves as an angiogenic factor and a downstream eff-
ecter of VEGF signaling.
The growth factors produced by the tumor cells act in an au-
tocrine manner by stimulating tumor cell migration, invasion and
proliferation. They also induce chemotaxis, proliferation and di-
fferentiation of inflammatory cells. Several cytokines and growth
factors that are secreted by the cells of the immune system often
act in concert to mediate immune and inflammatory responses,
and this leads to recruitment and activation of lymphocytes and
inflammatory cells at the sites of tumor. Although there have been
many studies about the roles and functions of these soluble cyto-
kines and growth factors at disease sites, there have been few re-
ports about the role of circulating soluble cytokines and the rela-
tionship between PBMCs and these factors in solid tumors. The
results of this current study suggest the possibility that the serum
levels of VEGF might be applicable as a reflection of the disease
status in HNSCC patients. Further, this study showed a significant
relationship between the expression of telomerase in PBMCs and
the serum VEGF. Further studies will be required to ascertain the
mechanism by which the telomerase activation of PBMCs is acti-
vated by circulating soluble growth factors.
The telomerase expression in the PBMCs of HNSCC patients
was significantly correlated with the N stage, the AJCC stage
and the prognosis. Although both the serum VEGF and MMP-9
levels of the HNSCC group were significantly higher than those
of the normal control group, only the serum VEGF level showed
a significant difference according to the T stage, the N stage, the
AJCC stage and the prognosis. This study showed a significant
relationship between the expression of telomerase in PBMCs and
the serum VEGF level. Further studies are required to assess the
relationship and interaction between serum VEGF and the telom-
erase expression in PBMCs. 
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